On Thursday, Larimar Therapeutics (NASDAQ:LRMR) shares received an Outperform rating from Wedbush with a price target set at $22. The biopharmaceutical company, focused on the development of treatments for complex rare diseases, has been recognized for its potential in addressing Friedreich's ataxia (FA), a challenging neurological disorder.
The rating was influenced by the recent nomination of Larimar's drug candidate, nomlabofusp, to the FDA’s START pilot program. This nomination is seen as a significant step, potentially expediting the drug's development and review process. Nomlabofusp, a frataxin replacement therapy, has shown promise in early data for treating FA. The therapy aims to tackle the underlying disease defect, and the success in heterozygous FA patients who demonstrate minimal to no symptoms suggests a favorable outcome for the drug.
Wedbush's analysis anticipates nomlabofusp could enter the market by FY27, with projections of reaching $1,502M in revenue by FY31. The firm's optimistic outlook is also supported by Larimar's robust financial position, with a strong balance sheet showing $226M in cash, which is expected to provide the company with enough funding into 2026.
The FDA's alignment on a path forward for nomlabofusp and the current stock price levels are considered to offer a favorable risk/reward scenario for risk-tolerant investors.
The target price of $22 reflects Wedbush's confidence in Larimar Therapeutics' potential, with the analyst setting a base case at this price level, while also outlining a bear case of $4 and a bull case of $27. The company's strategic positioning in the market for FA treatments is highlighted as a key factor in this positive assessment.
In other recent news, Larimar Therapeutics has been the focus of analyst attention, with both Jones Trading and Baird initiating coverage. Jones Trading issued a Buy rating with a $14.00 target price, expressing optimism for Larimar's primary product, nomlabofusp, currently in Phase 2 trials for treating Friedreich's Ataxia (FA). Jones Trading predicts nomlabofusp could reach $1.3 billion in peak unadjusted sales by 2031, with data from Phase 2 open label extension expected in late 2024 and throughout 2025.
Baird also initiated coverage on Larimar Therapeutics, assigning an Outperform rating and setting a $16.00 price target. Baird's outlook stemmed from the potential U.S. approval of nomlabofusp for treating FA, highlighting a 60% probability of the drug gaining approval, potentially with accelerated approval by 2026.
Both firms' decisions followed the U.S. Food and Drug Administration's inclusion of nomlabofusp in its START pilot program, designed to expedite the development and review of drugs treating serious conditions.
These recent developments reflect a positive outlook on Larimar Therapeutics' prospects within the FA treatment landscape, with both Jones Trading and Baird expressing confidence in the drug's ability to capture a significant market share. The unique mechanism of action of nomlabofusp, which directly targets the underlying cause of FA, a deficiency of the protein frataxin, is seen as a potential competitive edge in the market.
InvestingPro Insights
Larimar Therapeutics' (NASDAQ:LRMR) recent Outperform rating from Wedbush aligns with some of the financial data and insights provided by InvestingPro. The company's strong cash position, highlighted in the article, is reinforced by an InvestingPro Tip indicating that LRMR "holds more cash than debt on its balance sheet." This financial stability supports Wedbush's assertion that the company has sufficient funding into 2026.
However, investors should note that according to InvestingPro Data, Larimar's market capitalization stands at $401.34 million, significantly below Wedbush's projected revenue of $1,502 million by FY31. This gap suggests substantial growth potential if the company meets these projections, but also implies considerable risk.
An InvestingPro Tip warns that Larimar "suffers from weak gross profit margins" and is "not profitable over the last twelve months." This is consistent with the company's current development stage and focus on bringing nomlabofusp to market. The negative EBITDA of -$65.51 million for the last twelve months as of Q2 2024 further underscores the company's pre-revenue status.
Despite these challenges, LRMR has shown a "high return over the last year," with a 1-year price total return of 76.93% according to InvestingPro Data. This performance may reflect investor optimism about the company's potential, aligning with Wedbush's positive outlook.
For investors considering Larimar Therapeutics, it's worth noting that InvestingPro offers 9 additional tips that could provide further insights into the company's financial health and market position. These additional tips could be particularly valuable for assessing the risk/reward scenario mentioned in the Wedbush analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.